# AstraZeneca Teams Up With insitro in AI Drug Discovery Deal Worth Up to $1.5 Billion

- URL: https://stocks.freetheai.org/news/astrazeneca-teams-up-with-insitro-in-ai-drug-discovery-deal-worth-up-to-1-5-7e8fe9
- Published: 2026-10-15T10:53:57Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NYSE:AZN](https://stocks.freetheai.org/symbols/NYSE-AZN), [LSE:AZN](https://stocks.freetheai.org/symbols/LSE-AZN), [OTC:DSKYF](https://stocks.freetheai.org/symbols/OTC-DSKYF), [NASDAQ:SMMT](https://stocks.freetheai.org/symbols/NASDAQ-SMMT)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

AstraZeneca PLC (NYSE:AZN) entered into an artificial intelligence drug discovery and licensing agreement with California-based insitro that could be worth up to $1.5 billion. Under the terms of the deal, insitro will receive $40 million upfront and remains eligible for up to $1.46 billion in development and commercial milestone payments, alongside single-digit royalties on future global sales.

The partnership focuses on identifying and developing new treatments for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies, two medical fields with significant unmet needs. Insitro will use its Virtual Human AI platform to move AstraZeneca-nominated targets from initial discovery through early-stage development, while AstraZeneca holds exclusive global rights to commercialize any resulting programs.

Investors should monitor how effectively the AI-driven platform advances early targets into successful clinical trials. The agreement highlights a continued surge in business activity for AstraZeneca PLC, following its recent clinical collaboration with Daiichi Sankyo Company, Limited (OTC:DSKYF) and Summit Therapeutics Inc (NASDAQ:SMMT).

## Key points

- AstraZeneca PLC (NYSE:AZN) signed an AI drug discovery agreement worth up to $1.5 billion with California-based insitro.
- Insitro receives $40 million upfront and up to $1.46 billion in potential milestone payments, plus single-digit royalties on sales.
- The deal targets therapies for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.
- Insitro will use its Virtual Human AI platform for early development, while AstraZeneca retains exclusive global rights.

## Questions and answers

### How much is the AstraZeneca and insitro deal worth?

The deal is worth up to $1.5 billion. Insitro will receive $40 million upfront and up to $1.46 billion in milestone payments, along with potential single-digit royalties on global product sales.

### What diseases are AstraZeneca and insitro targeting?

The collaboration focuses on identifying and developing treatments for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies.

### What role will insitro play in the AstraZeneca partnership?

Insitro will use its Virtual Human AI platform to discover and advance AstraZeneca-nominated targets through early development, while AstraZeneca retains exclusive global commercial rights.